Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
80%(4 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
6
86%
Ph phase_2
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
6(85.7%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (85.7%)
Phase 21 (14.3%)

Trials by Status

active_not_recruiting114%
terminated114%
completed571%

Recent Activity

1 active trials
Showing 5 of 7
terminatedphase_2

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

NCT02364713
active_not_recruitingphase_1

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
completedphase_1

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

NCT02700230
completedphase_1

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00408590
completedphase_1

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

NCT01846091
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02364713Phase 2

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Terminated
NCT02068794Phase 1

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active Not Recruiting
NCT02700230Phase 1

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Completed
NCT00408590Phase 1

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed
NCT01846091Phase 1

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Completed
NCT01503177Phase 1

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Completed
NCT00450814Phase 1

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7